JP2008539791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539791A5 JP2008539791A5 JP2008512518A JP2008512518A JP2008539791A5 JP 2008539791 A5 JP2008539791 A5 JP 2008539791A5 JP 2008512518 A JP2008512518 A JP 2008512518A JP 2008512518 A JP2008512518 A JP 2008512518A JP 2008539791 A5 JP2008539791 A5 JP 2008539791A5
- Authority
- JP
- Japan
- Prior art keywords
- biological sample
- level
- therapeutic agent
- biomarker
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150013553 CD40 gene Proteins 0.000 claims 75
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 75
- 239000012472 biological sample Substances 0.000 claims 74
- 238000000034 method Methods 0.000 claims 74
- 239000000090 biomarker Substances 0.000 claims 48
- 239000003814 drug Substances 0.000 claims 47
- 229940124597 therapeutic agent Drugs 0.000 claims 46
- 210000004027 cell Anatomy 0.000 claims 40
- 108010029697 CD40 Ligand Proteins 0.000 claims 29
- 102100032937 CD40 ligand Human genes 0.000 claims 29
- 239000000523 sample Substances 0.000 claims 25
- 230000000694 effects Effects 0.000 claims 17
- 238000012360 testing method Methods 0.000 claims 16
- 230000019491 signal transduction Effects 0.000 claims 13
- 208000023275 Autoimmune disease Diseases 0.000 claims 10
- 230000006907 apoptotic process Effects 0.000 claims 10
- 208000027866 inflammatory disease Diseases 0.000 claims 10
- 230000001404 mediated effect Effects 0.000 claims 10
- 210000004369 blood Anatomy 0.000 claims 9
- 239000008280 blood Substances 0.000 claims 9
- 239000012503 blood component Substances 0.000 claims 7
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 6
- 230000004083 survival effect Effects 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 230000008901 benefit Effects 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 229950004563 lucatumumab Drugs 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 230000008569 process Effects 0.000 claims 4
- 230000009467 reduction Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 102000043136 MAP kinase family Human genes 0.000 claims 3
- 108091054455 MAP kinase family Proteins 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 108091007065 BIRCs Proteins 0.000 claims 2
- 102000051485 Bcl-2 family Human genes 0.000 claims 2
- 108700038897 Bcl-2 family Proteins 0.000 claims 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 2
- 102000011727 Caspases Human genes 0.000 claims 2
- 108010076667 Caspases Proteins 0.000 claims 2
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 2
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000013467 fragmentation Methods 0.000 claims 2
- 238000006062 fragmentation reaction Methods 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 230000007730 Akt signaling Effects 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 108010063916 CD40 Antigens Proteins 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 108090000567 Caspase 7 Proteins 0.000 claims 1
- 102100029855 Caspase-3 Human genes 0.000 claims 1
- 102100038902 Caspase-7 Human genes 0.000 claims 1
- 102100026550 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000024781 Immune Complex disease Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 102000000763 Survivin Human genes 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims 1
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 239000000158 apoptosis inhibitor Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 239000000306 component Substances 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000037902 enteropathy Diseases 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 claims 1
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 208000001875 irritant dermatitis Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 238000013042 tunel staining Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68257505P | 2005-05-18 | 2005-05-18 | |
| US60/682,575 | 2005-05-18 | ||
| US74933605P | 2005-12-09 | 2005-12-09 | |
| US60/749,336 | 2005-12-09 | ||
| PCT/US2006/019325 WO2006125117A2 (en) | 2005-05-18 | 2006-05-18 | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008539791A JP2008539791A (ja) | 2008-11-20 |
| JP2008539791A5 true JP2008539791A5 (enExample) | 2009-07-02 |
| JP5421590B2 JP5421590B2 (ja) | 2014-02-19 |
Family
ID=36968724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512518A Expired - Fee Related JP5421590B2 (ja) | 2005-05-18 | 2006-05-18 | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8333970B2 (enExample) |
| EP (2) | EP1889065B1 (enExample) |
| JP (1) | JP5421590B2 (enExample) |
| AU (1) | AU2006247134B2 (enExample) |
| CA (1) | CA2608750A1 (enExample) |
| DK (1) | DK1889065T3 (enExample) |
| ES (1) | ES2429564T3 (enExample) |
| HR (1) | HRP20130852T1 (enExample) |
| PL (1) | PL1889065T3 (enExample) |
| PT (1) | PT1889065E (enExample) |
| WO (1) | WO2006125117A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003067210A2 (en) | 2001-07-10 | 2003-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detecting the activation state of the multiple proteins in single cells |
| US7381535B2 (en) | 2002-07-10 | 2008-06-03 | The Board Of Trustees Of The Leland Stanford Junior | Methods and compositions for detecting receptor-ligand interactions in single cells |
| US7393656B2 (en) * | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| US8945564B2 (en) | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| WO2009059259A2 (en) * | 2007-10-31 | 2009-05-07 | Children's Hospital Medical Center | Detection of worsening renal disease in subjects with systemic lupus erythematosus |
| US9068230B2 (en) | 2007-11-07 | 2015-06-30 | Genentech, Inc. | Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
| NZ586834A (en) | 2008-01-18 | 2013-03-28 | Methods of detecting signatures of disease or conditions in bodily fluids | |
| EP2352998A4 (en) | 2008-11-07 | 2011-09-21 | Centocor Ortho Biotech Inc | MARKERS AND METHOD FOR THE STUDY AND TREATMENT OF LIGHT-SENSITIVELY LUPUS PATIENTS |
| KR20110110247A (ko) * | 2008-12-30 | 2011-10-06 | 센토코 오르토 바이오테크 인코포레이티드 | 강직성 척추염 환자에서 항-ＴＮＦα 항체에 대한 임상적 반응을 예측하는 혈청 마커 |
| JP5302054B2 (ja) * | 2009-03-06 | 2013-10-02 | オリンパス株式会社 | Ｄｎａが断片化されたアポトーシス細胞の検出方法、細胞画像解析装置、及びプログラム |
| ES2605228T3 (es) | 2009-04-18 | 2017-03-13 | Genentech, Inc. | Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 |
| WO2011006119A2 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| JP2013520208A (ja) * | 2010-02-24 | 2013-06-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 自己免疫疾患の診断、予後判定、及び処置法 |
| EP2796563A1 (en) * | 2010-05-04 | 2014-10-29 | MedImmune, LLC | Optimized degenerative muscle disease diagnostics and treatments |
| US20120040846A1 (en) | 2010-07-23 | 2012-02-16 | President And Fellows Of Harvard College | Methods of Detecting Diseases or Conditions Using Phagocytic Cells |
| KR20130041961A (ko) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액에서 질환 또는 상태의 특징을 검출하는 방법 |
| EP2596116A4 (en) | 2010-07-23 | 2014-03-19 | Harvard College | METHOD FOR DETECTING AUTOIMMUNE OR AUTOIMMUNE DISORDERS OR SUFFERING |
| WO2012012717A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| US20120196762A1 (en) * | 2011-01-27 | 2012-08-02 | Paradis Norman A | Method and apparatus for discovery, development and clinical application of multiplex assays based on patterns of cellular response |
| MX339239B (es) | 2011-04-29 | 2016-05-18 | Apexigen Inc | Anticuerpos anti-cd40 y metodos de uso. |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| WO2014042981A2 (en) * | 2012-09-17 | 2014-03-20 | Digital Therapeutics Llc | Treating digital ulcers, hypertension, vasculitis conditions, or inflammatory myositis conditions |
| AU2013337903B2 (en) | 2012-10-30 | 2018-08-16 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| NZ771629A (en) | 2013-03-09 | 2022-12-23 | Harry Stylli | Methods of detecting cancer |
| EP3385717A3 (en) | 2013-03-09 | 2018-10-24 | Harry Stylli | Methods of detecting prostate cancer |
| TWI502199B (zh) * | 2013-05-23 | 2015-10-01 | Univ Nat Central | 腫瘤壞死因子受體相關因子７作爲紅斑性狼瘡的生物標記物之用途、偵測人體患有紅斑性狼瘡的方法以及偵測人體患有紅斑性狼瘡的套組 |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| AU2015314813B2 (en) | 2014-09-11 | 2022-02-24 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
| ES2885476T3 (es) * | 2015-10-05 | 2021-12-13 | Ucb Biopharma Sprl | Firmas moleculares para uso en diagnóstico y análisis de respuesta al tratamiento de enfermedades autoinmunes |
| US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
| US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
| WO2018026442A1 (en) * | 2016-08-01 | 2018-02-08 | The Regents Of The University Of California | Small molecule inhibition for preventing or treating fibrotic diseases |
| JP2021528393A (ja) | 2018-06-15 | 2021-10-21 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の上昇 |
| US20210261678A1 (en) * | 2018-06-29 | 2021-08-26 | Boehringer Ingelheim International Gmbh | Anti-cd40 antibodies for use in treating autoimmune disease |
| WO2020102721A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als) |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| JP2021518854A (ja) * | 2019-05-08 | 2021-08-05 | ノバルティス アーゲー | Ｔ１ｄｍ及び膵島炎の治療に使用するための抗ｃｄ４０抗体 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| EP4256087A4 (en) * | 2020-12-02 | 2024-12-04 | Albert Einstein College of Medicine | METHOD FOR PREDICTING PATIENT RESPONSE TO CD40-TARGETED THERAPIES |
| CN112860824B (zh) * | 2021-01-15 | 2021-12-10 | 中国科学院沈阳应用生态研究所 | 一种高分辨率dem地形特征提取的尺度适应性评价方法 |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| CA3233863A1 (en) | 2021-10-04 | 2023-04-13 | Arasteh AZHIR | Treatment methods for als patients |
| CA3257247A1 (en) * | 2022-05-27 | 2023-11-30 | Eledon Pharmaceuticals, Inc. | METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| DK0604552T3 (da) | 1991-09-18 | 1997-08-04 | Affymax Tech Nv | Fremgangsmåde til syntese af forskellige samlinger af oligomerer |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| JP3190042B2 (ja) | 1991-10-31 | 2001-07-16 | マトリテク インコーポレイテッド | 核マトリックス蛋白液アッセー |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| EP1588761A3 (en) | 1991-11-22 | 2005-11-23 | Affymetrix, Inc. | Method of forming arrays of polymers |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| US5540926A (en) | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US20020086321A1 (en) | 1993-02-02 | 2002-07-04 | Craig Ruth W. | Myeloid cell leukemia associated gene MCL-1 |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| WO1995006666A1 (en) | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Anti-gp39 antibodies and uses therefor |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1995017202A1 (en) | 1993-12-23 | 1995-06-29 | Immunex Corporation | Method of preventing or treating disease characterized by neoplastic cells expressing cd40 |
| JPH09510088A (ja) | 1994-03-03 | 1997-10-14 | アレクション・ファーマシューティカル・インク | 最終補体インヒビター融合遺伝子およびタンパク質 |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US6156535A (en) | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| GB9601108D0 (en) | 1996-01-19 | 1996-03-20 | Univ Ottawa | Neuronal apoptosis inhibitor protein (NAIP) |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| WO1997032601A1 (fr) | 1996-03-06 | 1997-09-12 | Chugai Seiyaku Kabushiki Kaisha | Procede de criblage de substances induisant l'apoptose |
| US6245523B1 (en) | 1996-11-20 | 2001-06-12 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
| CZ295805B6 (cs) | 1997-06-20 | 2005-11-16 | Biogen Idec Ma Inc. | Léčivý přípravek obsahující monoklonální protilátku anti-CD154 nebo její derivát pro léčení syndromu inhibice exogenního proteinu |
| WO1999023254A1 (en) | 1997-10-31 | 1999-05-14 | Affymetrix, Inc. | Expression profiles in adult and fetal organs |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| DK1079824T3 (da) * | 1998-05-19 | 2011-11-21 | Res Dev Foundation | Triterpen-sammensætninger og fremgangsmåder til anvendelse deraf |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| CN1437478A (zh) | 2000-04-25 | 2003-08-20 | Idec药物公司 | 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗 |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| CA2419841A1 (en) | 2000-09-01 | 2002-03-07 | Biogen, Inc. | Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| US7288252B2 (en) | 2000-10-02 | 2007-10-30 | Novartis Vaccines And Diagnostics, Inc. | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
| ATE374214T1 (de) | 2001-04-27 | 2007-10-15 | Kirin Brewery | Monoklonaler anti-cd-40-antikörper |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1575574A4 (en) * | 2002-10-30 | 2007-11-07 | Blood Res Center | METHOD FOR TREATING AND PREVENTING APOPTOSIS-BASED DISEASES BY MEANS OF RNA INTERFERENCE AGENTS |
| GB0301566D0 (en) * | 2003-01-23 | 2003-02-26 | Eirx Therapeutics Ltd | Kinasaes and GPCRs involved in apoptosis |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| ATE476448T1 (de) * | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung |
| EP1718602A4 (en) * | 2004-01-30 | 2007-12-12 | Peplin Biolipids Pty Ltd | THERAPEUTIC AND CARRIER MOLECULES |
| US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
-
2006
- 2006-05-18 DK DK06770605.1T patent/DK1889065T3/da active
- 2006-05-18 CA CA002608750A patent/CA2608750A1/en not_active Abandoned
- 2006-05-18 ES ES06770605T patent/ES2429564T3/es active Active
- 2006-05-18 EP EP06770605.1A patent/EP1889065B1/en active Active
- 2006-05-18 HR HRP20130852TT patent/HRP20130852T1/hr unknown
- 2006-05-18 AU AU2006247134A patent/AU2006247134B2/en not_active Ceased
- 2006-05-18 PT PT67706051T patent/PT1889065E/pt unknown
- 2006-05-18 EP EP10187778A patent/EP2312315A1/en not_active Withdrawn
- 2006-05-18 US US11/914,710 patent/US8333970B2/en not_active Expired - Fee Related
- 2006-05-18 WO PCT/US2006/019325 patent/WO2006125117A2/en not_active Ceased
- 2006-05-18 JP JP2008512518A patent/JP5421590B2/ja not_active Expired - Fee Related
- 2006-05-18 PL PL06770605T patent/PL1889065T3/pl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008539791A5 (enExample) | ||
| US7157235B2 (en) | Methods of diagnosis, prognosis and treatment of cardiovascular disease | |
| US10877049B2 (en) | Biomarkers for diagnosis and management of neuro-immunological diseases | |
| JP5421590B2 (ja) | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 | |
| JP2008539794A5 (enExample) | ||
| US8178304B2 (en) | Diagnostic methods relating to Graves' disease and other autoimmune disorders | |
| JP7221264B2 (ja) | Ｃｄ６結合パートナーの使用およびそれに基づく方法 | |
| US8415111B2 (en) | Methods of evaluating BAFF | |
| KR20050072126A (ko) | Ｉｌ―１７ 생성의 억제 | |
| WO2011100637A1 (en) | Markers for determination of patient responsiveness | |
| JP2010536043A5 (enExample) | ||
| JP2012504245A (ja) | リンホトキシンアンタゴニストに対する関節リウマチの応答性を予測する生物学的マーカー | |
| CN104870012A (zh) | 用于炎性疾病的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 | |
| KR20150134414A (ko) | 베타7 인테그린 길항제를 사용하는 위장 염증성 장애의 치료를 평가하기 위한 바이오마커의 사용 | |
| Pacifico et al. | Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease | |
| JP2023181255A (ja) | 疾病の予後と管理のための方法 | |
| JP2015001534A (ja) | 抗腫瘍壊死因子アルファ（ｔｎｆ）治療に対する応答性の予想のためのバイオマーカー | |
| JP2018025554A (ja) | 炎症性疾患のマーカー | |
| EP3170000B1 (en) | Method for treating rheumatoid arthritis | |
| Kireta et al. | Cross-reactivity of anti-human chemokine receptor and anti-TNF family antibodies with common marmoset (Callithrix jacchus) leukocytes | |
| KR20220080124A (ko) | 생물학적 요법에 대한 요구를 예측하는 방법 | |
| CN115104029A (zh) | 用于检测和监测全身性炎症的非侵入性测定法 | |
| Lee et al. | Detection of Anti‐Cytokine Autoantibodies and Clinical Applications | |
| Idica | The temporal relationship of B-cell activating factor to human leukocyte antigen-specific antibodies | |
| MX2007014069A (es) | Uso de enlace de anticuerpo-ligando para caracterizar enfermedades. |